Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
25 01 2021
Historique:
received: 22 05 2020
accepted: 22 12 2020
entrez: 26 1 2021
pubmed: 27 1 2021
medline: 9 2 2021
Statut: epublish

Résumé

Tumour necrosis factor (TNF) is a trimeric protein which signals through two membrane receptors, TNFR1 and TNFR2. Previously, we identified small molecules that inhibit human TNF by stabilising a distorted trimer and reduce the number of receptors bound to TNF from three to two. Here we present a biochemical and structural characterisation of the small molecule-stabilised TNF-TNFR1 complex, providing insights into how a distorted TNF trimer can alter signalling function. We demonstrate that the inhibitors reduce the binding affinity of TNF to the third TNFR1 molecule. In support of this, we show by X-ray crystallography that the inhibitor-bound, distorted, TNF trimer forms a complex with a dimer of TNFR1 molecules. This observation, along with data from a solution-based network assembly assay, leads us to suggest a model for TNF signalling based on TNF-TNFR1 clusters, which are disrupted by small molecule inhibitors.

Identifiants

pubmed: 33495441
doi: 10.1038/s41467-020-20828-3
pii: 10.1038/s41467-020-20828-3
pmc: PMC7835368
doi:

Substances chimiques

Receptors, Tumor Necrosis Factor, Type I 0
Small Molecule Libraries 0
TNF protein, human 0
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

582

Références

Cell. 2007 Feb 9;128(3):533-46
pubmed: 17289572
Nat Struct Mol Biol. 2010 Nov;17(11):1324-9
pubmed: 20935634
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
J Med Chem. 2017 Apr 27;60(8):3511-3517
pubmed: 28300404
Bioinformatics. 2004 Nov 22;20(17):3289-91
pubmed: 15217809
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Cell. 1993 May 7;73(3):431-45
pubmed: 8387891
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Nat Struct Biol. 2003 Dec;10(12):980
pubmed: 14634627
Lymphokine Cytokine Res. 1993 Jun;12(3):143-8
pubmed: 8394147
Nat Commun. 2019 Dec 19;10(1):5795
pubmed: 31857588
Science. 2005 Nov 11;310(5750):1022-5
pubmed: 16284179
J Biol Chem. 1994 Sep 9;269(36):22492-5
pubmed: 8077196
J Biol Chem. 1995 Jun 2;270(22):13303-7
pubmed: 7768931
Nat Rev Immunol. 2015 Jun;15(6):362-74
pubmed: 26008591
Science. 2000 Jun 30;288(5475):2351-4
pubmed: 10875917
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
Biochemistry. 2012 Aug 21;51(33):6545-55
pubmed: 22799488
Sci Signal. 2020 Jan 14;13(614):
pubmed: 31937565
J Biol Chem. 1990 Aug 25;265(24):14497-504
pubmed: 1696947
Cell. 2000 Jun 23;101(7):777-87
pubmed: 10892748
Trends Biochem Sci. 2002 Jan;27(1):19-26
pubmed: 11796220
Mol Cell Proteomics. 2011 Jan;10(1):M110.002808
pubmed: 20852190
Cell. 1990 Apr 20;61(2):361-70
pubmed: 2158863
J Biol Chem. 1995 Jan 6;270(1):387-91
pubmed: 7529234
Sci Signal. 2018 Jan 02;11(511):
pubmed: 29295955
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
ACS Chem Biol. 2011 Jun 17;6(6):636-47
pubmed: 21417339
Cytokine. 2007 Feb;37(2):101-7
pubmed: 17449269
Cell Death Differ. 2015 Nov;22(11):1727-41
pubmed: 26292758
Biotechnol Prog. 2013 May-Jun;29(3):697-706
pubmed: 23335490
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):570-5
pubmed: 9435233
Clin Rheumatol. 2006 Jul;25(4):448-52
pubmed: 16362448
Structure. 1996 Nov 15;4(11):1251-62
pubmed: 8939750
Microsc Res Tech. 2000 Aug 1;50(3):184-95
pubmed: 10891884
FEBS Lett. 2001 Mar 16;492(3):171-6
pubmed: 11257489

Auteurs

David McMillan (D)

UCB Pharma, Slough, SL1 3WE, UK. david.mcmillan@ucb.com.

Carlos Martinez-Fleites (C)

UCB Pharma, Slough, SL1 3WE, UK.
GlaxoSmithKline, Stevenage, SG1 2NY, UK.

John Porter (J)

UCB Pharma, Slough, SL1 3WE, UK.

David Fox (D)

UCB Pharma, Bainbridge Island, WA, 98110, USA.

Rachel Davis (R)

UCB Pharma, Slough, SL1 3WE, UK.

Prashant Mori (P)

UCB Pharma, Slough, SL1 3WE, UK.

Tom Ceska (T)

UCB Pharma, Slough, SL1 3WE, UK.

Bruce Carrington (B)

UCB Pharma, Slough, SL1 3WE, UK.

Alastair Lawson (A)

UCB Pharma, Slough, SL1 3WE, UK.

Tim Bourne (T)

UCB Pharma, Slough, SL1 3WE, UK.

James O'Connell (J)

UCB Pharma, Slough, SL1 3WE, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH